TGA approves Delcath Hepatic Chemosat delivery system
The Therapeutic Goods Administration (TGA), a division of Australian government, has granted approval to Delcath Systems' Hepatic Chemosat delivery system.
Delcath's delivery system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.
Delcath Systems president and CEO Eamonn Hobbs said they believe chemosaturation therapy via their Chemosat system will provide an important treatment alternative for liver cancer patients in the Australian market.
The company has received CE mark for its Chemosat system in April 2011 and has completed the product notification process with the Medicines and Medical Device Safety Authority in New Zealand in October 2011.
Related Insight
Suppliers Directory
Diagnostics In Vitro Diagnostics Diagnostic Imaging Endoscopy Devices
Patient Care Patient Monitoring Surgical & Supplies Wound Care Management
Technology Automation Healthcare IT Packaging
Contract Services
Certification
Drug Delivery Devices Intelligence
GlobalData’s new report, “External Defibrillators - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2016” provides key data, information and analysis on the global external defibrillators market. The report provides market landscape, competitive landscape and market trends information the external defibrillators market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.